STOCKS TELEGRAPH

Tag: ABVC Stock Price

  • Why ABVC BioPharma Stock Is On The Rise Today

    Why ABVC BioPharma Stock Is On The Rise Today

    ABVC BioPharma Inc. (NASDAQ: ABVC) is experiencing a remarkable surge in its current trading session. As of the last check, ABVC BioPharma’s stock has soared by an impressive 270.25%, reaching a valuation of $3.15 per share. This substantial upswing in ABVC’s stock price can be directly attributed to a significant global licensing endeavor.

    ABVC BioPharma (ABVC) has formally entered into a legally binding term sheet establishing a comprehensive, multi-year global licensing pact with AiBtl BioPharma, denoted as AiBtl. The agreement encompasses ABVC’s Central Nervous System (CNS) pharmaceuticals, specifically tailored for treating Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD).

    The proposed licensing arrangement will encompass clinical trial oversight, registration, manufacturing, supply, and distribution rights for the Licensed Products. The Licensed Products related to MDD and ADHD, both held by ABVC and its subsidiary BioLite, Inc., have been assessed at an impressive valuation of $667 million by an impartial third-party evaluation.

    ABVC and AiBtl are unequivocally committed to fostering a global synergy in the development of these Licensed Products. Furthermore, they are dedicated to reinforcing their collaboration in novel drug development and business strategies, including technological innovation, interoperability, and standards advancement.

    Under the binding term sheet, ABVC’s licensing revenues, pertaining to both ABVC and its subsidiary BioLite, Inc., will comprise 46 million shares of AiBtl stock (representing 57% ownership of AiBtl) and milestone cash disbursements amounting to $7 million, coupled with a 5% royalty on net sales, capped at $200 million, post-launch.

    An essential facet of AiBtl’s collaborative initiative is the fusion of health and resort industries. Moreover, the partnership aims to leverage revenue streams emanating from land leases within the Asia Economic Development Zone.

    AiBtl possesses considerable expertise in global business expansion, and this affiliation with ABVC will facilitate the establishment of alliances with international pharmaceutical entities for the advancement of the Licensed Products and the subsequent introduction of CNS medications into the market.

    In tandem, this association will allow ABVC BioPharma to maintain its focus on launching other proprietary patented products, such as ophthalmological medical devices like Vitargus and oncology drugs, into the global market.

  • Why ABVC BioPharma (ABVC) Stock Is Rocketing Today?

    ABVC BioPharma, Inc. (NASDAQ: ABVC) experienced a significant surge of 47.63% in its stock price during the early trading session, reaching $5.61, marking a notable increase of $1.81 from the previous market close. Throughout the session, the stock hit a low of $5.11 and reached a peak of $6.87 per share.

    In a major announcement today, ABVC BioPharma revealed its plans for a strategic partnership with Zhonghui United Technology (Zhonghui) Group Co., Ltd. and its affiliated enterprises.

    The proposed collaboration involves an equity transfer deal, valuing real estate assets at approximately $7.4 million. The primary objective behind this partnership is to establish a large-scale health and wellness base in Chengdu, China.

    The intended partnership aims to create an integrated platform fostering cooperation between researchers and industry leaders.

    As part of the agreement, ABVC BioPharma plans to transfer common shares to Zhonghui at $20 per share, entitling them to a twenty percent ownership of Zhonghui’s property near Chengdu, valued at $37 million by an independent valuation company, and a piece of land already owned by Zhonghui in the same area.

    The signing of the term sheet with Zhonghui, a wholly owned corporation founded in 2020 with substantial assets totaling $4.4 billion, an annual revenue of $4.2 billion, and a net profit of $757 million, represents a major milestone for ABVC BioPharma.

    With this initiative, ABVC aims to establish a comprehensive facility, fostering collaborations between industry, academia, and research, and promoting innovation, knowledge exchange, and sustainable development in rural areas surrounding Chengdu. ABVC’s expertise in Oncology/Hematology, Neurology, and Ophthalmology will further aid its global expansion efforts.

    ABVC’s subsidiary, BioKey, Inc., has entered the second year of a 3-year agreement to manufacture dietary supplements derived from Maitake mushrooms in tablet and liquid forms.

    The partnership with Define Biotech Co. Ltd. has proven fruitful, with BioKey set to receive USD $1.0 million amid the increasing demand for mushroom-based nutritional supplements. This agreement grants Define Biotech the right to distribute the Maitake mushroom-containing nutritional supplement in China and Taiwan.

    ABVC’s prowess in conducting clinical trials has enabled them to extract Maitake mushroom ingredients with unmatched purity and consistency compared to competitors.

    The production of dietary supplements serves as a promising revenue stream for ABVC BioPharma while concurrently advancing clinical trials for their other drug candidates. ABVC BioPharma’s recent surge in stock price, strategic partnership with Zhonghui, and successful dietary supplement ventures reflect the company’s dedication to innovation and global expansion, with a focus on advancing health and wellness initiatives in the pharmaceutical and nutraceutical realms.